May 10, 2023 07:11 AM EDT
R&D

Boehringer brings ear­ly da­ta for GLP-1 re­cep­tor show­ing al­most 15% weight loss af­ter 46 weeks

Katherine Lewin

News Reporter

Boehringer In­gel­heim and Zealand Phar­ma re­leased Phase II da­ta on their weight loss can­di­date, a glucagon and GLP-1 re­cep­tor ag­o­nist called …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times